BIOMARKER-INTEGRATED DIAGNOSTIC ALGORITHM TO REDUCE MISCLASSIFICATION IN PEDIATRIC DEMYELINATING DISORDERS
Open Access
- 31 March 2026
- journal article
- Published by South Kazakhstan Medical Academy in Central Asian Journal of Medical Hypotheses and Ethics
- Vol. 7 (1) , 79-85
Abstract
Background: Pediatric acquired demyelinating disorders of the central nervous system, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein–associated disease (MOGAD), represent a heterogeneous group of immune-mediated conditions with overlapping clinical and radiological features. Accurate differentiation among these entities is critical due to differences in immunopathogenesis, prognosis, and therapeutic strategies. In regions with variable access to advanced serological testing, diagnostic misclassification remains a significant concern. Objective: To develop a structured, biomarker-integrated diagnostic framework for pediatric demyelinating disorders adapted to Central Asian healthcare settings. Methods: This study employed a conceptual analysis grounded in international diagnostic criteria (IPMSSG, McDonald, and NMOSD) and contemporary neuroimmunology literature. A scenario-based modeling approach was used to identify high-risk clinical phenotypes associated with diagnostic uncertainty and to construct a stepwise algorithm incorporating anti–aquaporin-4 (AQP4-IgG) and anti–myelin oligodendrocyte glycoprotein (MOG-IgG) antibody testing. Results: The proposed diagnostic algorithm prioritizes early recognition of clinical “red flags,” including opticospinal phenotypes and longitudinally extensive spinal cord lesions, followed by stepwise serological evaluation before definitive application of MS diagnostic criteria. This framework has the potential to reduce diagnostic misclassification and support phenotype-specific therapeutic decision-making in resource-limited environments. Conclusion: A biomarker-integrated diagnostic approach may enhance diagnostic accuracy and treatment safety in pediatric demyelinating disorders in Central Asia. Prospective validation studies are warranted to evaluate the real-world impact of this framework on clinical outcomes.Keywords
This publication has 10 references indexed in Scilit:
- Pediatric Multiple Sclerosis: Changing the Trajectory of ProgressionCurrent Neurology and Neuroscience Reports, 2023
- Pediatric Multiple SclerosisSeminars in Pediatric Neurology, 2023
- Clinical and Genetic Analysis in Pediatric Patients with Multiple Sclerosis and Related Conditions: Focus on DR Genes of the Major Histocompatibility ComplexThe Open Neurology Journal, 2022
- Pediatric multiple sclerosis – current status of epidemiology, diagnosis and treatmentNeurologia i Neurochirurgia Polska, 2020
- Relapsing Demyelinating Syndromes in Children: A Practical Review of Neuroradiological MimicsFrontiers in Neurology, 2020
- Pediatric Multiple Sclerosis: an UpdateCurrent Neurology and Neuroscience Reports, 2018
- Predictors of Development of Juvenile Multiple Sclerosis in Kazakh Population According to the DR-Genes of Major Histocompatibility ComplexJournal of Neurology and Experimental Neuroscience, 2018
- Pediatric multiple sclerosisCurrent Opinion in Neurology, 2017
- International consensus diagnostic criteria for neuromyelitis optica spectrum disordersNeurology, 2015
- International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitionsMultiple Sclerosis Journal, 2013